VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

30 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

23 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

08 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming Investor Conferences

12 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

07 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

05 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

17 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

16 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming September Investor Conferences

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

13 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  

30 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

24 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

18 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

18 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

27 Jun 2024 01:00:03 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present in Upcoming June Investor Conferences

30 May 2024 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

08 May 2024 06:40:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 15:05:01 By Nasdaq GlobeNewswire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

17 Apr 2024 15:05:00 By Nasdaq GlobeNewswire